Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Market Reports
NEW
 Top 50 Non-Healthcare Market Reports
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Hereditary Angioedema Therapeutics Global Market Report 2025
Download Free Sample Buy Now
Global Hereditary Angioedema Therapeutics Market Report 2025

Report Price : $4490.00

Pages :

Format : PDF

Published : December 2025

Delivery Time : 2-3 Business Days

Purchase This Report Download Sample PDF
Purchase This Report

Hereditary Angioedema Therapeutics Global Market Report 2025

By Drug Class (C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes), By Route of Administration (Intravenous, Subcutaneous, Oral), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels), By Application (Prophylaxis, On-demand) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Hereditary Angioedema Therapeutics Market Overview

• Hereditary Angioedema Therapeutics market size has reached to $6.68 billion in 2024

• Expected to grow to $15.84 billion in 2029 at a compound annual growth rate (CAGR) of 19.5%

• Growth Driver: Surging Prevalence Of Hereditary Angioedema Ignites Growth In The Market

• Market Trend: Innovative Therapeutic Advancements Shape The Landscape Of Hereditary Angioedema Market

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Hereditary Angioedema Therapeutics Market?

Hereditary angioedema (HAE) therapeutics refers to therapy for an autosomal dominant condition brought on by a deficiency in or malfunction of the C1-inhibitor protein. Hereditary angioedema symptoms include angioedema-related upper airway, cutaneous, and, or gastrointestinal complaints.

The main drug classes of hereditary angioedema therapeutics are C1 esterase inhibitor, selective bradykinin B2 receptor antagonist, kallikrein inhibitor, others. C1 Esterase Inhibitor refers to a protein called that is present in the fluid portion of blood and it regulates the complement system's protein C1, which goes by the name of C1. The therapeutics are administered through intravenous, Subcutaneous, and oral, distributed via Hospital Pharmacy, retail pharmacy, and others. The application of hereditary angioedema therapeutics include prophylaxis and on-demand.

Hereditary Angioedema Therapeutics Market Size and growth rate 2025 to 2029: Graph

What Is The Hereditary Angioedema Therapeutics Market Size 2025 And Growth Rate?

The hereditary angioedema therapeutics market size has grown rapidly in recent years. It will grow from$6.68 billion in 2024 to $7.77 billion in 2025 at a compound annual growth rate (CAGR) of 16.3%. The growth in the historic period can be attributed to improved diagnosis and awareness, treatment access expansion, research and development initiatives, patient advocacy and education, and regulatory approvals

What Is The Hereditary Angioedema Therapeutics Market Growth Forecast?

The hereditary angioedema therapeutics market size is expected to see rapid growth in the next few years. It will grow to $15.84 billion in 2029 at a compound annual growth rate (CAGR) of 19.5%. The growth in the forecast period can be attributed to advancements in targeted therapies, global market expansion, gene therapy developments, personalized medicine trends, and collaboration in research and treatment. Major trends in the forecast period include global access initiatives, health economic outcomes research, early intervention strategies, and pediatric HAE therapeutics.

The forecast of 19.5% growth over the next five years reflects a modest reduction of 0.2% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. rare disease patients by driving up the cost of C1 esterase inhibitor concentrates and bradykinin receptor antagonists imported from Switzerland and Austria, increasing acute attack management costs and emergency care utilization. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Pharmaceuticals Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

How Is The Hereditary Angioedema Therapeutics Market Segmented?

1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes

2) By Route of Administration: Intravenous, Subcutaneous, Oral

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

4) By Application: Prophylaxis, On-demand

Subsegments:

1) By C1 Esterase Inhibitor: Plasma-Derived, Recombinant

2) By Selective Bradykinin B2 Receptor Antagonist: Icatibant

3) By Kallikrein Inhibitor: Ecallantide, Lanadelumab

4) By Other Drug Classes: Emerging Therapies

What Is Driving The Hereditary Angioedema Therapeutics Market? Surging Prevalence Of Hereditary Angioedema Ignites Growth In The Market

The rising prevalence of hereditary angioedema is expected to propel the growth of the hereditary angioedema market going forward. Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of severe swelling of the skin and mucous membranes. The swelling is caused by excess fluid build-up (EDEMA) and can occur anywhere in the body, including the hands and feet, face, intestines, and airways. For Instance, in June 2022, according to Rare Disease Advisor, an online resource company that provides health care professionals, globally, 1 in every 50,000 persons suffer from hereditary angioedema with prevalence estimates ranging from 1:10,000 to 1:150,000. HAE episodes cause 15,000 to 30,000 emergency room visits each year in the US. 5.8% of cases of HAE had an average time to diagnosis of 0 to 6 months, whereas 5.8% had an average time to diagnosis of over 10 years. Therefore, the rising prevalence of hereditary angioedema is driving the growth of the hereditary angioedema market.

What Is Driving The Hereditary Angioedema Therapeutics Market? Growth Of The Hereditary Angioedema Therapeutics Market Driven By Increasing Healthcare Expenditure

The increasing healthcare expenditure is expected to boost the growth of the hereditary angioedema therapeutics market going forward. Healthcare expenditure refers to the total amount of resources, including financial resources, spent on healthcare goods and services within a specific period in a given geographical area. Greater healthcare expenditure allows for increased investment in research and development activities focused on understanding the underlying causes of hereditary angioedema and developing innovative therapeutic solutions. For instance, in December 2022, according to the Centers for Medicare & Medicaid Services, a US-based federal agency, U.S. healthcare spending grew by 4.1% to $4.5 trillion in 2022, which is faster than the 3.2% increase in 2021. Therefore, the increasing healthcare expenditure is driving the growth of the hereditary angioedema therapeutics industry.

Who Are The Major Players In The Global Hereditary Angioedema Therapeutics Market?

Major companies operating in the hereditary angioedema therapeutics market include Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., CENTOGENE N.V., GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., AbbVie Inc., Incyte Corporation, BioMarin Pharmaceutical Inc., Dyax Corp., Salix Pharmaceuticals Inc., Pharvaris N.V., Innovent Biologics Inc., AstraZeneca plc, BeiGene Ltd., Jiangsu HenGrui Medicine Co. Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG., Exelixis Inc., Lev Pharmaceuticals Inc., Kedrion Biopharma Inc., Pharos Pharmaceuticals Inc.

What Are The Key Trends Of The Global Hereditary Angioedema Therapeutics Market? Innovative Therapeutic Advancements Shape The Landscape Of Hereditary Angioedema Market

Product innovations are a key trend gaining popularity in the hereditary angioedema therapeutics market. Major companies operating in the hereditary angioedema therapeutics market are developing innovative products such as ligand-conjugated (LICA) investigational antisense medicine and gene therapy to sustain their position in the market. For Instance, in March 2023, Intellia Therapeutics, a US-based clinical-stage biotechnology company, launched an Investigational New Drug (IND) NTLA-2002, which was approved by the United States Food and Drug Administration for the treatment of hereditary angioedema. This enables the company's ongoing Phase 1/2 trial to include the US in the worldwide Phase 2 part. After a single dose of therapy, the inactivation of the target gene, kallikrein B1 (KLKB1), will permanently lower plasma kallikrein protein activity and prevent HAE attacks. NTLA-2002 is a candidate for in vivo genome editing.

What Are The Key Trends Of The Global Hereditary Angioedema Therapeutics Market? Innovative Oral Treatments Transforming Management of Hereditary Angioedema

Major companies operating in the hereditary angioedema (HAE) therapeutics market are developing innovative treatments, such as oral plasma kallikrein inhibitors, to enhance patient management and provide effective, on-demand options for alleviating HAE attacks, thereby improving overall patient outcomes and quality of life. Oral plasma kallikrein inhibitors are drugs taken by mouth that inhibit the enzyme plasma kallikrein, helping to manage and reduce the severity of hereditary angioedema attacks. For instance, in September 2024, KalVista Pharmaceuticals, a US-based biopharmaceutical company, received US. Food and Drug Administration of New drug application for Sebetralstat, aiming to offer HAE patients a more convenient, non-invasive treatment alternative to intravenous or subcutaneous medications. This solution meets the growing demand for fast, effective oral treatments that can be administered immediately during an hereditary angioedema attack.

Need data on a specific region in this market?
Request Regional Data

Hereditary Angioedema Therapeutics Market Merger And Acquisition: Takeda Pharmaceutical Company Acquired Nimbus Lakshmi Inc.

In February 2023, Takeda Pharmaceutical Company, a Japan-based pharmaceutical company, acquired Nimbus Lakshmi Inc. from Nimbus Therapeutics LLC for an undisclosed amount. This acquisition strengthens Takeda's growing late-stage pipeline to expand its portfolio and patient impact across multiple indications and maintains strong global growth over the medium to long term. Nimbus Lakshmi, a fully-owned subsidiary of Nimbus Therapeutics, is a US-based company that provides Tyrosine kinase 2 (TYK2) inhibitor NDI-034858.

Regional Analysis For The Global Hereditary Angioedema Therapeutics Market

North America was the largest region in the global hereditary angioedema therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Hereditary Angioedema Therapeutics Market?

The hereditary angioedema therapeutics market includes revenues earned by entities by diagnosis and evaluation, treatment, and management of hereditary angioedema. The market value includes the value of related goods sold by the service provider or included within the service offering. The hereditary angioedema therapeutics market also includes of sales of tranexamic acid, danazol, intravenous and subcutaneous nano-filtered purified plasma-derived human C1 esterase inhibitor concentrate, and lanadelumab. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Hereditary Angioedema Therapeutics Industry?

The hereditary angioedema therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hereditary angioedema therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Hereditary Angioedema Therapeutics Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $7.77 billion
Revenue Forecast In 2034 $15.84 billion
Growth Rate CAGR of 19.5% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes
2) By Route of Administration: Intravenous, Subcutaneous, Oral
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
4) By Application: Prophylaxis, On-demand Subsegments: 1) By C1 Esterase Inhibitor: Plasma-Derived, Recombinant
2) By Selective Bradykinin B2 Receptor Antagonist: Icatibant
3) By Kallikrein Inhibitor: Ecallantide, Lanadelumab
4) By Other Drug Classes: Emerging Therapies
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., CENTOGENE N.V., GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., AbbVie Inc., Incyte Corporation, BioMarin Pharmaceutical Inc., Dyax Corp., Salix Pharmaceuticals Inc., Pharvaris N.V., Innovent Biologics Inc., AstraZeneca plc, BeiGene Ltd., Jiangsu HenGrui Medicine Co. Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG ., Exelixis Inc., Lev Pharmaceuticals Inc., Kedrion Biopharma Inc., Pharos Pharmaceuticals Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Hereditary Angioedema Therapeutics Market Characteristics

3. Hereditary Angioedema Therapeutics Market Trends And Strategies

4. Hereditary Angioedema Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Hereditary Angioedema Therapeutics Growth Analysis And Strategic Analysis Framework

5.1. Global Hereditary Angioedema Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Hereditary Angioedema Therapeutics Market Growth Rate Analysis

5.4. Global Hereditary Angioedema Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Hereditary Angioedema Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Hereditary Angioedema Therapeutics Total Addressable Market (TAM)

6. Hereditary Angioedema Therapeutics Market Segmentation

6.1. Global Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

C1 Esterase Inhibitor

Selective Bradykinin B2 Receptor Antagonist

Kallikrein Inhibitor

Other Drug Classes

6.2. Global Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Intravenous

Subcutaneous

Oral

6.3. Global Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacy

Retail Pharmacy

Other Distribution Channels

6.4. Global Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Prophylaxis

On-demand

6.5. Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of C1 Esterase Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Plasma-Derived

Recombinant

6.6. Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Selective Bradykinin B2 Receptor Antagonist, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Icatibant

6.7. Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Kallikrein Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Ecallantide

Lanadelumab

6.8. Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Emerging Therapies

7. Hereditary Angioedema Therapeutics Market Regional And Country Analysis

7.1. Global Hereditary Angioedema Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Hereditary Angioedema Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hereditary Angioedema Therapeutics Market

8.1. Asia-Pacific Hereditary Angioedema Therapeutics Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hereditary Angioedema Therapeutics Market

9.1. China Hereditary Angioedema Therapeutics Market Overview

9.2. China Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hereditary Angioedema Therapeutics Market

10.1. India Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hereditary Angioedema Therapeutics Market

11.1. Japan Hereditary Angioedema Therapeutics Market Overview

11.2. Japan Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hereditary Angioedema Therapeutics Market

12.1. Australia Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hereditary Angioedema Therapeutics Market

13.1. Indonesia Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hereditary Angioedema Therapeutics Market

14.1. South Korea Hereditary Angioedema Therapeutics Market Overview

14.2. South Korea Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hereditary Angioedema Therapeutics Market

15.1. Western Europe Hereditary Angioedema Therapeutics Market Overview

15.2. Western Europe Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hereditary Angioedema Therapeutics Market

16.1. UK Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hereditary Angioedema Therapeutics Market

17.1. Germany Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hereditary Angioedema Therapeutics Market

18.1. France Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hereditary Angioedema Therapeutics Market

19.1. Italy Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hereditary Angioedema Therapeutics Market

20.1. Spain Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hereditary Angioedema Therapeutics Market

21.1. Eastern Europe Hereditary Angioedema Therapeutics Market Overview

21.2. Eastern Europe Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hereditary Angioedema Therapeutics Market

22.1. Russia Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hereditary Angioedema Therapeutics Market

23.1. North America Hereditary Angioedema Therapeutics Market Overview

23.2. North America Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hereditary Angioedema Therapeutics Market

24.1. USA Hereditary Angioedema Therapeutics Market Overview

24.2. USA Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hereditary Angioedema Therapeutics Market

25.1. Canada Hereditary Angioedema Therapeutics Market Overview

25.2. Canada Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hereditary Angioedema Therapeutics Market

26.1. South America Hereditary Angioedema Therapeutics Market Overview

26.2. South America Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hereditary Angioedema Therapeutics Market

27.1. Brazil Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hereditary Angioedema Therapeutics Market

28.1. Middle East Hereditary Angioedema Therapeutics Market Overview

28.2. Middle East Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hereditary Angioedema Therapeutics Market

29.1. Africa Hereditary Angioedema Therapeutics Market Overview

29.2. Africa Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hereditary Angioedema Therapeutics Market Competitive Landscape And Company Profiles

30.1. Hereditary Angioedema Therapeutics Market Competitive Landscape

30.2. Hereditary Angioedema Therapeutics Market Company Profiles

30.2.1. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Pharming Healthcare Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Attune Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Adverum Biotechnologies Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Arrowhead Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Hereditary Angioedema Therapeutics Market Other Major And Innovative Companies

31.1. Ionis Pharmaceuticals Inc.

31.2. BioCryst Pharmaceuticals Inc.

31.3. CSL Behring LLC

31.4. KalVista Pharmaceutical Inc.

31.5. CENTOGENE N.V.

31.6. GlaxoSmithKline plc.

31.7. Eli Lilly and Company

31.8. Amgen Inc.

31.9. AbbVie Inc.

31.10. Incyte Corporation

31.11. BioMarin Pharmaceutical Inc.

31.12. Dyax Corp.

31.13. Salix Pharmaceuticals Inc.

31.14. Pharvaris N.V.

31.15. Innovent Biologics Inc.

32. Global Hereditary Angioedema Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hereditary Angioedema Therapeutics Market

34. Recent Developments In The Hereditary Angioedema Therapeutics Market

35. Hereditary Angioedema Therapeutics Market High Potential Countries, Segments and Strategies

35.1 Hereditary Angioedema Therapeutics Market In 2029 - Countries Offering Most New Opportunities

35.2 Hereditary Angioedema Therapeutics Market In 2029 - Segments Offering Most New Opportunities

35.3 Hereditary Angioedema Therapeutics Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of C1 Esterase Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Selective Bradykinin B2 Receptor Antagonist, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Kallikrein Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Hereditary Angioedema Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Hereditary Angioedema Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Asia-Pacific, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: China, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: India, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Japan, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Australia, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Indonesia, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: South Korea, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: Western Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: UK, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: Germany, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: France, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Italy, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Spain, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Eastern Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Russia, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: North America, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: USA, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: Canada, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: South America, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Brazil, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Middle East, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Africa, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Sanofi S.A. Financial Performance
  • Table 80: Pharming Healthcare Inc. Financial Performance
  • Table 81: Attune Pharmaceuticals Inc. Financial Performance
  • Table 82: Adverum Biotechnologies Inc. Financial Performance
  • Table 83: Arrowhead Pharmaceuticals Inc. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of C1 Esterase Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Selective Bradykinin B2 Receptor Antagonist, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Kallikrein Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Hereditary Angioedema Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Hereditary Angioedema Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Asia-Pacific, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: China, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: India, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Japan, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Australia, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Indonesia, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: South Korea, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: Western Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: UK, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: Germany, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: France, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Italy, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Spain, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Eastern Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Russia, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: North America, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: USA, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: Canada, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: South America, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Brazil, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Middle East, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Africa, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Sanofi S.A. Financial Performance
  • Figure 80: Pharming Healthcare Inc. Financial Performance
  • Figure 81: Attune Pharmaceuticals Inc. Financial Performance
  • Figure 82: Adverum Biotechnologies Inc. Financial Performance
  • Figure 83: Arrowhead Pharmaceuticals Inc. Financial Performance

Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Forecast 2025–2034: Trends Reshaping Demand, Investment, and Innovation

Read More About Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Forecast 2025–2034: Trends Reshaping Demand, Investment, and Innovation

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Projected to Reach $47.74 Billion by 2029 at a CAGR of 30.7%

Read More About Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Projected to Reach $47.74 Billion by 2029 at a CAGR of 30.7%

$8.21 Billion Forecast for Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market by 2029, Backed by Demand and Innovation

Read More About $8.21 Billion Forecast for Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market by 2029, Backed by Demand and Innovation

Fentanyl Market Forecast Reaching $22.03 Billion by 2029 at 6.5% CAGR

Read More About Fentanyl Market Forecast Reaching $22.03 Billion by 2029 at 6.5% CAGR

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

Read More About A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

Read More About A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

Read More About A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Read More About A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Hereditary Angioedema Therapeutics Global Market Report 2025 – By Drug Class (C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes), By Route of Administration (Int...

View Report

Angina Pectoris Drugs Global Market Report 2025 – By Drugs (Nitrates, Antiplatelet Agents, Beta-adrenergic Blocking Agents, Calcium Channel Blockers, Anti-ischemic Agents, Statins, Antihypertensive Agents, Other Drugs), ...

View Report

Angina Global Market Report 2025 – By Type (Angina Pectoris, Unstable Angina, Prinzmetal Angina, Other Types), By Treatment (Lifestyle Changes, Medications, Angioplasty And Stenting, Coronary Bypass Surgery, Other Treatm...

View Report

Biopsy Devices Global Market Report 2025 – By Product Type (Needle-Based Biopsy Guns, Biopsy Forceps, Biopsy Guidance Systems, Biopsy Needles, Other Products), By Image Guiding Technology (MRI-Guided Biopsy, Stereotactic...

View Report

Angina Pectoris Drugs Global Market Report 2025 – By Drugs (Nitrates, Antiplatelet Agents, Beta-adrenergic Blocking Agents, Calcium Channel Blockers, Anti-ischemic Agents, Statins, Antihypertensive Agents, Other Drugs), ...

View Report

Hereditary Breast and Ovarian Cancer Syndrome Treatment Global Market Report 2025 – By Treatment (Hormonal Therapy, Chemoprevention, Genetic Counselling, Medication, Other Treatments), By Diagnosis (Genetic Testing, Magn...

View Report

Hereditary Cancer Testing Global Market Report 2025 – By Test Type( Multi Panel Test, Single-site Genetic Test), By Indication( Breast Cancer, Ovarian Cancer, Colorectal Cancer, Other Indications), By End user( Hospital,...

View Report

Peripheral Arterial Disease Global Market Report 2025 – By Treatment Type (Devices, Catheters, Drugs, Other Types), By Route of Administration (Oral, Parenteral, Other Route of Administrations), By End User (Hospitals, S...

View Report

Frequently Asked Questions

Hereditary angioedema (HAE) therapeutics refers to therapy for an autosomal dominant condition brought on by a deficiency in or malfunction of the C1-inhibitor protein. Hereditary angioedema symptoms include angioedema-related upper airway, cutaneous, and, or gastrointestinal complaints. For further insights on this market, request a sample here

The market major growth driver - Surging Prevalence Of Hereditary Angioedema Ignites Growth In The Market. For further insights on this market, request a sample here

The hereditary angioedema therapeutics market size has grown rapidly in recent years. It will grow from $6.68 billion in 2024 to $7.77 billion in 2025 at a compound annual growth rate (CAGR) of 16.3%. The growth in the historic period can be attributed to improved diagnosis and awareness, treatment access expansion, research and development initiatives, patient advocacy and education, and regulatory approvals The hereditary angioedema therapeutics market size is expected to see rapid growth in the next few years. It will grow to " $15.84 billion in 2029 at a compound annual growth rate (CAGR) of 19.5%. The growth in the forecast period can be attributed to advancements in targeted therapies, global market expansion, gene therapy developments, personalized medicine trends, and collaboration in research and treatment. Major trends in the forecast period include global access initiatives, health economic outcomes research, early intervention strategies, and pediatric HAE therapeutics. For further insights on this market, request a sample here

The hereditary angioedema therapeutics market covered in this report is segmented –
1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes
2) By Route of Administration: Intravenous, Subcutaneous, Oral
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
4) By Application: Prophylaxis, On-demand Subsegments:
1) By C1 Esterase Inhibitor: Plasma-Derived, Recombinant
2) By Selective Bradykinin B2 Receptor Antagonist: Icatibant
3) By Kallikrein Inhibitor: Ecallantide, Lanadelumab
4) By Other Drug Classes: Emerging Therapies For further insights on this market, request a sample here

North America was the largest region in the global hereditary angioedema therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on this market, request a sample here.

Major companies operating in the hereditary angioedema therapeutics market include Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., CENTOGENE N.V., GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., AbbVie Inc., Incyte Corporation, BioMarin Pharmaceutical Inc., Dyax Corp., Salix Pharmaceuticals Inc., Pharvaris N.V., Innovent Biologics Inc., AstraZeneca plc, BeiGene Ltd., Jiangsu HenGrui Medicine Co. Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG ., Exelixis Inc., Lev Pharmaceuticals Inc., Kedrion Biopharma Inc., Pharos Pharmaceuticals Inc. . For further insights on this market, request a sample here.

Major trends in this market include Innovative Therapeutic Advancements Shape The Landscape Of Hereditary Angioedema Market. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Hereditary Angioedema Therapeutics Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top WhatsApp icon